DVAX
Dynavax Technologies CorporationNASDAQHealthcare$15.50+0.00%ClosedMarket Cap: $1.82B
As of 2026-04-04
Valuation
P/E (TTM)
—
PEG
—
P/B
3.40
P/S
5.51
EV/EBITDA
-75.83
DCF Value
$-22.27
FCF Yield
4.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
83.2%
Operating Margin
3.2%
Net Margin
-13.1%
ROE
-8.1%
ROA
-4.6%
ROIC
1.2%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q3 2025 | $94.9M | 84.8% | $21.3M | $26.9M | $0.21 | — |
| Q2 2025 | $95.4M | 85.3% | $14.4M | $18.7M | $0.14 | — |
| Q1 2025 | $68.2M | 79.8% | $-23.6M | $-96.1M | $-0.77 | — |
| Q4 2024 | $72.0M | 81.4% | $-1.6M | $7.0M | $0.05 | — |
| FY 2024 | $277.2M | 82.2% | $-4.1M | $27.3M | $0.20 | — |
| Q3 2024 | $80.6M | 83.8% | $10.1M | $17.6M | $0.11 | — |
| Q2 2024 | $73.8M | 83.8% | $6.1M | $11.4M | $0.08 | — |
| Q1 2024 | $50.8M | 78.4% | $-17.8M | $-8.7M | $-0.07 | — |
| Q4 2023 | $55.6M | 84.4% | $-8.5M | $219.0K | $0.00 | — |
| FY 2023 | $232.3M | 78.4% | $-37.0M | $-6.4M | $-0.05 | — |
| Q3 2023 | $69.5M | 81.0% | $5.1M | $14.3M | $0.09 | — |
| Q2 2023 | $60.2M | 77.5% | $-3.4M | $3.4M | $0.03 | — |